Journal of Clinical Oncology, Vol 15, 2981-2995, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors

DM Savarese, C Hsieh and FM Stewart
Division of Hematology/Oncology and the Cancer Center, University of Massachusetts Medical Center, Worcester 01655, USA. diane.savarese@bangate.ummed.edu

PURPOSE: To review published controlled clinical trials examining the benefit of escalated chemotherapy in patients with hematologic and solid malignancies. METHODS: Studies were obtained by searching Medline and CancerLit and by review of bibliographies of published trials. We reviewed studies that examined dose-intense (DI) chemotherapy alone, in combination with hematopoietic colony-stimulating factors (CSFs), or high-dose therapy (HDT) with autologous bone marrow support (ABMT). RESULTS: DI therapy without CSF or ABMT has not been shown to improve overall outcome in any tumor except consolidative therapy of acute myelogenous leukemia (AML). In solid tumors, many published studies suggest that less than standard-intensity chemotherapy is suboptimal, but few studies that examined higher compared with standard-dose therapy have shown a significant difference in outcome. No studies have convincingly demonstrated improved overall survival (OS) with DI therapy with CSF support. The use of HDT with ABMT has been shown to improve survival in multiple myeloma (MM), as well as relapsed intermediate- and high-grade non-Hodgkin's lymphoma (NHL). High-dose chemotherapy with ABMT is promising in patients with metastatic breast cancer (MBC), but it should not yet be considered a standard approach for these patients. CONCLUSION: DI chemotherapy is an acceptable and standard therapeutic maneuver for patients with AML in first remission, MM, and relapsed aggressive NHL. In solid tumors, the use of DI chemotherapy either alone or with cytokine support has not been shown to improve outcome and should not be considered standard therapy. Current randomized trials should provide definitive answers about the role of DI therapy in solid tumors.

This article has been cited by other articles:

				I. J. Lewis, M. A. Nooij, J. Whelan, M. R. Sydes, R. Grimer, P. C. W. Hogendoorn, M. A. Memon, S. Weeden, B. M. Uscinska, M. van Glabbeke, et al. Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup J Natl Cancer Inst, January 17, 2007; 99(2): 112 - 128. [Abstract] [Full Text] [PDF]

				J. P. Monk, G. Phillips, R. Waite, J. Kuhn, L. J. Schaaf, G. A. Otterson, D. Guttridge, C. Rhoades, M. Shah, T. Criswell, et al. Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients J. Clin. Oncol., April 20, 2006; 24(12): 1852 - 1859. [Abstract] [Full Text] [PDF]

				L. Del Mastro, M. Venturini, R. Lionetto, F. Carnino, D. Guarneri, L. Gallo, A. Contu, P. Pronzato, L. Vesentini, M. Bergaglio, et al. Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Compared With Standard CEF in Metastatic Breast Cancer Patients: Results of a Multicenter, Randomized Phase III Study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group J. Clin. Oncol., April 15, 2001; 19(8): 2213 - 2221. [Abstract] [Full Text] [PDF]

				L. S. Elting, E. B. Rubenstein, C. G. Martin, D. Kurtin, S. Rodriguez, E. Laiho, K. Kanesan, S. B. Cantor, and R. S. Benjamin Incidence, Cost, and Outcomes of Bleeding and Chemotherapy Dose Modification Among Solid Tumor Patients With Chemotherapy-Induced Thrombocytopenia J. Clin. Oncol., February 15, 2001; 19(4): 1137 - 1146. [Abstract] [Full Text] [PDF]

				I. J. Lewis, S. Weeden, D. Machin, D. Stark, and A. W. Craft Received Dose and Dose-Intensity of Chemotherapy and Outcome in Nonmetastatic Extremity Osteosarcoma J. Clin. Oncol., December 15, 2000; 18(24): 4028 - 4037. [Abstract] [Full Text] [PDF]

				H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585. [Full Text] [PDF]

				B. Schiedlmeier, K. Kuhlcke, H. G. Eckert, C. Baum, W. J. Zeller, and S. Fruehauf Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice Blood, February 15, 2000; 95(4): 1237 - 1248. [Abstract] [Full Text] [PDF]

				C. L. Bennett, J. A. Weeks, M. R. Somerfield, J. Feinglass, and T. J. Smith Use of Hematopoietic Colony-Stimulating Factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology Surveys Regarding ASCO Clinical Practice Guidelines J. Clin. Oncol., November 1, 1999; 17(11): 3676 - 3681. [Abstract] [Full Text] [PDF]

				A. Palumbo, S. Triolo, C. Argentino, S. Bringhen, A. Dominietto, C. Rus, P. Omede, C. Tarella, A. Pileri, and M. Boccadoro Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients Blood, August 15, 1999; 94(4): 1248 - 1253. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky On Pushing the Outer Edge of the Outer Edge of Paclitaxel's Dosing Envelope Clin. Cancer Res., March 1, 1999; 5(3): 481 - 486. [Full Text] [PDF]